NLM Digital Collections

Search

Start Over Subjects Prognosis ✖Remove constraint Subjects: Prognosis Dates by Range 2000 and later ✖Remove constraint Dates by Range: 2000 and later

1. Diagnostic tests for Alzheimer's disease: generating and evaluating evidence to inform insurance coverage policy

Author(s):
Pearson, Steven D., author
Ollendorf, Daniel A., author
Colby, Jennifer A., author
Publication:
[Boston, MA] : Institute for Clinical and Economic Review, [2012]
Subject(s):
Alzheimer Disease -- diagnosis
Diagnostic Tests, Routine -- methods
Evidence-Based Practice
Insurance Coverage
Biomarkers
Biomedical Research -- methods
Clinical Protocols
Clinical Trials as Topic -- methods
Early Diagnosis
Insurance, Health
Neuropsychological Tests
Outcome Assessment (Health Care)
Patient Outcome Assessment
Policy Making
Practice Guidelines as Topic
Predictive Value of Tests
Prognosis
Randomized Controlled Trials as Topic
Reproducibility of Results
Translational Medical Research -- methods
Humans
United States

2. Assessment of COVID-19 in primary care: the identification of symptoms, signs, characteristics, comorbidities and clinical signs in adults, children and young people, which may indicate a higher risk of progression to severe disease : evidence review

Publication:
[Edinburgh, Scotland] : Scottish Intercollegiate Guidelines Network (SIGN), February 3, 2021
Subject(s):
COVID-19 -- complications
Disease Progression
Patient Acuity
Primary Health Care
Prognosis
Adult
Child
Young Adult
Scotland

3. Enrichment strategies for clinical trials to support determination of effectiveness of human drugs and biological products

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, March 2019
Subject(s):
Clinical Trials as Topic
Prognosis
Research Design
Biomarkers, Pharmacological
Biomarkers, Tumor
Captopril -- therapeutic use
Cardiovascular Diseases -- drug therapy
Clozapine -- therapeutic use
Cyclooxygenase 2 Inhibitors -- therapeutic use
Drugs, Investigational
Lung Diseases -- drug therapy
Medication Adherence
Neoplasms -- drug therapy
Patient Compliance
Patient Selection
Pharmacogenetics
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.

4. Hematologic malignancies: regulatory considerations for use of minimal residual disease in development of drug and biological products for treatment

Publication:
Silver Spring, MD : Center for Drug Evaluation and Research, January 2020
Subject(s):
Biomarkers
Clinical Trials as Topic
Drug Approval
Drug Development
Drugs, Investigational
Hematologic Neoplasms -- drug therapy
Investigational New Drug Application
Neoplasm, Residual
Endpoint Determination
Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
Leukemia, Myeloid, Acute -- drug therapy
Leukemia, Promyelocytic, Acute -- drug therapy
Multiple Myeloma -- drug therapy
Patient Selection
Precursor Cell Lymphoblastic Leukemia-Lymphoma -- drug therapy
Prognosis
Humans
United States
United States. Department of Health and Human Services.
United States. Food and Drug Administration.